The most common chronic wounds include venous leg ulcers (Ulcera cruris), diabetic foot syndrome and pressure sores. In addition to the considerable costs of the respective standard treatment, these wounds are usually infected with germs that require the additional use of antibiotics.
- The average costs for a grade 1 decubitus are €1.489, €6.162 for grade 2, €10.238 for grade 3 and €14.771 for a grade 4 decubitus1, the latter for a treatment period of at least 180 days.
- The average costs for leg ulcers are €9.060 per year.2
- The average costs for DFU amounted to €1.293 in the first quarter of the new diagnosis plus rising follow-up costs. If an amputation is required, the costs increase by € 14.284 plus follow-up costs.3
According to the WHO, 25.000 people die each year in Europe from infections with multi-resistant pathogens. Treating patients with multi-resistant pathogens costs the European Union around €1.5 billion annually. One reason for the growing resistance to antibiotics is the increased consumption of antibiotics worldwide.Globally, it has increased by 36 percent between 2000
- Deutsche Antibiotika- Resistenzstrategie (DART), Bundesministerium für Gesundheit, April 2011, erweitert 2015
- With de K, Allerberger F, Amann S, et al. S3 Leitlinie Antibiotika Anwendung im Krankenhaus.
- Altmeyers Enzyklopädie, Std: 25.3.2019
- Streit M et al., Infektionen chronischer Wunden, ZfW 2009 Nr.3, S. 172
Since 2011, western countries like Germany have been advocating a systematic reduction in the use of antibiotics. ¹ In Germany a S3 guideline on the rational use of antibiotics (antibiotic stewardship) has been in place since December 2013.²
In the treatment of chronic wounds, the local application of antibiotics is already no longer standard of care and thus obsolete. Local application of antibiotics can lead to the development of polyvalent contact allergies, the formation of resistance and thus a decisive disturbance of wound healing. ³
Systemic antibiotic therapy is only indicated if MRSA is detected and a wound infection is present. Reserve antibiotics are used for this purpose.⁴
Biofilm is a complex microbial community of bacteria and fungi that forms a viscous matrix of sugar and proteins to protect against external threats. 60 to 90% of all chronic wounds have a biofilm.
Biofilms stimulate a chronic inflammatory reaction as the body's immune response and thereby impede wound healing. The resulting increase in wound exudation helps the biofilm to improve its nutritional situation. The biofilm is therefore better able to establish itself in the wound.
To date, there is no one-step solution to eliminate biofilms.¹
PATHELEN® Hybrid is the first one-step solution for the efficient removal of biofilm.
PATHELEN® Hybrid is a wound therapy containing both hydrophilic and hydrophobic silica. The extra large surface structure of the silica (1 bottle of Pathelen Hybrid contains 2g with a surface area of approx. 600 m²) generates an extra high capillary action for the adsorption of biofilm, wound exudate, toxins and pathogenic germs. This ensures fast and efficient physical wound cleaning.
PATHELEN® Hybrid is a medical device class I registered with SWISSMEDIC and US FDA and approved in the EU, Turkey, Canada, EFTA and USA.
In recent years, the PATHELEN® HYBRID therapy has been tested on patients in various hospitals and has been continuously developed. A wide variety of wound infections were successfully treated until the patient had completely healed and recovered.
Case studies of successful treatments for MRSA infected wounds
Don't have an account yet? Request one at: email@example.com